Company Description
Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company that develops orally administered biologics for patients, physicians, and healthcare systems in the United States.
The company develops the RaniPill capsule, a drug-agnostic oral delivery platform to deliver a variety of drug substances, including oligonucleotides, peptides, proteins, and antibodies.
Its product pipeline includes RT-102, a parathyroid hormone that is in Phase I clinical trial for the treatment of osteoporosis; RT-105, an anti-TNF-alpha antibody that is in preclinical studies to treat psoriatic arthritis; RT-110, a parathyroid hormone for the treatment of hypoparathyroidism; and RT-111, an ustekinumab biosimilar for the treatment of various inflammatory conditions.
Rani Therapeutics Holdings, Inc. was founded in 2012 and is headquartered in San Jose, California.
| Country | United States |
| Founded | 2012 |
| IPO Date | Jul 30, 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 140 |
| CEO | Talat Imran |
Contact Details
Address: 2051 Ringwood Avenue San Jose, California 95131 United States | |
| Phone | (408) 457-3700 |
| Website | ranitherapeutics.com |
Stock Details
| Ticker Symbol | RANI |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $11.00 |
| CIK Code | 0001856725 |
| CUSIP Number | 753018100 |
| ISIN Number | US7530181004 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Mir A. Imran | Executive Chairman |
| Talat Imran | Chief Executive Officer and Director |
| Svai S. Sanford | Chief Financial Officer |
| Dr. Mir Hashim | Chief Scientific Officer |
| Eric Groen | General Counsel |
| Bella Vazquez | Vice President of Human Resources |
| Kate McKinley M.B.A. | Chief Business Officer |
| Arvinder Dhalla | Vice President of Clinical Development |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 17, 2024 | ARS | Filing |
| Apr 17, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 17, 2024 | DEF 14A | Other definitive proxy statements |
| Mar 20, 2024 | S-8 | Securities to be offered to employees in employee benefit plans |
| Mar 20, 2024 | 10-K | Annual Report |
| Mar 20, 2024 | 8-K | Current Report |
| Feb 5, 2024 | 8-K | Current Report |
| Dec 19, 2023 | 8-K | Current Report |
| Dec 14, 2023 | 8-K | Current Report |
| Dec 8, 2023 | SC 13D/A | [Amend] General statement of acquisition of beneficial ownership |